Table 1 Characteristics of the included patients (n = 335)
Characteristics | |
|---|---|
Sex (n = 329), Male, n (%) | 211 (64.1) |
Age, year (n = 310) | 53.4 ± 20.1 |
Cause of ESRD (n = 222) | |
DMN, n (%) | 77 (34.7) |
CGN, n (%) | 54 (24.3) |
HT, n (%) | 30 (13.5) |
Hypoplasia, n (%) | 13 (5.8) |
PKD, n (%) | 7 (3.2) |
PD duration, month (n = 247) | 25.4 ± 28.6 |
Past history of PD-related infection (n = 275) | |
PD catheter-related infection only, n (%) | 71 (25.8) |
PD-related peritonitis only, n (%) | 13 (4.7) |
Both PD catheter-related infection and PD-related peritonitis, n (%) | 14 (5.1) |
Past history of NTM infection (n = 267) | 14 (5.2) |
Causative pathogen (n = 319) | |
M. abscessus, n (%) | 128 (40.1) |
M. fortuitum, n (%) | 79 (24.8) |
M. chelonae, n (%) | 53 (16.6) |
M. avium, n (%) | 15 (4.7) |
M. gordonae, n (%) | 4 (1.3) |
Diagnosis (n = 303) | |
PD catheter-related infection only, n (%) | 130 (42.9) |
PD-related peritonitis only, n (%) | 85 (28.1) |
Both PD catheter-related infection and PD-related peritonitis, n (%) | 88 (29.0) |
Initial culture result for diagnosis (n = 278) | |
[Group 1] positive for NTM, n (%) | 157 (56.5) |
[Group 2] positive for any other bacteria, n (%) | 55 (19.8) |
[Group 3] negative, n (%) | 66 (23.7) |
Antibiotics Therapy (n = 294) | |
Number of antimicrobial use | |
0, n (%) | 9 (3.1) |
1, n (%) | 49 (16.7) |
2, n (%) | 126 (42.9) |
3, n (%) | 93 (31.6) |
4, n (%) | 17 (5.8) |
Types of antimicrobial use | |
Macrolide antimicrobial use, n (%) | 200 (68.0) |
Aminoglycoside antimicrobial use, n(%) | 156 (53.1) |
Quinolone antimicrobial use, n (%) | 146 (49.6) |
Beta-lactam antimicrobial use, n (%) | 132 (44.9) |
Rifampicin antimicrobial use, n (%) | 31 (10.5) |
Tetracycline antimicrobial use, n (%) | 29 (9.9) |
Ethambutol antimicrobial use, n (%) | 25 (8.5) |
Linezolid/Tedizolid antimicrobial use, n (%) | 14 (4.8) |
Sulfamethoxazole Trimethoprim antimicrobial use, n (%) | 11 (3.7) |